Abstract
The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γrises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin-2 typically increases the peak level of interferon-γfourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2of interleukin-2/day results in interferon-γlevels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon-γlevels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γlevels.
Original language | English (US) |
---|---|
Pages (from-to) | 55-63 |
Number of pages | 9 |
Journal | Journal of Immunotherapy |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1992 |
Externally published | Yes |
Keywords
- Interferon-β
- Interferon-γ Cancer
- Interleukin-2
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
- Cancer Research